FR2587720A2 - Vaccin contre le syndrome immunodeficitaire acquis et intermediaires immunogeniques pour la preparation de ce vaccin et pour des dosages immunologiques de depistage de ce syndrome - Google Patents

Vaccin contre le syndrome immunodeficitaire acquis et intermediaires immunogeniques pour la preparation de ce vaccin et pour des dosages immunologiques de depistage de ce syndrome Download PDF

Info

Publication number
FR2587720A2
FR2587720A2 FR8613414A FR8613414A FR2587720A2 FR 2587720 A2 FR2587720 A2 FR 2587720A2 FR 8613414 A FR8613414 A FR 8613414A FR 8613414 A FR8613414 A FR 8613414A FR 2587720 A2 FR2587720 A2 FR 2587720A2
Authority
FR
France
Prior art keywords
virus
recombinant
lav
htlv iii
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8613414A
Other languages
English (en)
French (fr)
Other versions
FR2587720B2 (zh
Inventor
Hu Shiu-Lok
Anthony F Purchio
Linda Madisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of FR2587720A2 publication Critical patent/FR2587720A2/fr
Application granted granted Critical
Publication of FR2587720B2 publication Critical patent/FR2587720B2/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR8613414A 1985-09-25 1986-09-25 Vaccin contre le syndrome immunodeficitaire acquis et intermediaires immunogeniques pour la preparation de ce vaccin et pour des dosages immunologiques de depistage de ce syndrome Granted FR2587720A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (2)

Publication Number Publication Date
FR2587720A2 true FR2587720A2 (fr) 1987-03-27
FR2587720B2 FR2587720B2 (zh) 1995-02-10

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8613414A Granted FR2587720A2 (fr) 1985-09-25 1986-09-25 Vaccin contre le syndrome immunodeficitaire acquis et intermediaires immunogeniques pour la preparation de ce vaccin et pour des dosages immunologiques de depistage de ce syndrome

Country Status (22)

Country Link
CN (1) CN1020752C (zh)
AT (1) ATA256786A (zh)
CH (1) CH676247A5 (zh)
DE (1) DE3690508T1 (zh)
DK (1) DK455486A (zh)
ES (2) ES2002490A6 (zh)
FI (1) FI863848A (zh)
FR (1) FR2587720A2 (zh)
GB (1) GB2181435B (zh)
GR (1) GR862412B (zh)
HU (1) HU205780B (zh)
IE (1) IE59314B1 (zh)
IL (1) IL80073A (zh)
IT (1) IT1195829B (zh)
MY (1) MY103182A (zh)
NL (1) NL8602422A (zh)
NO (1) NO863803L (zh)
NZ (1) NZ217645A (zh)
PT (1) PT83434B (zh)
SE (4) SE8604007L (zh)
WO (1) WO1987002038A1 (zh)
YU (1) YU46753B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650011T2 (de) * 1985-04-08 1994-11-17 Genetic Systems Corp EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND.
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ES2056054T3 (es) * 1986-09-19 1994-10-01 Oncogen Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida.
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
ES2104556T3 (es) * 1987-01-16 1997-10-16 Pasteur Institut Peptidos que tienen propiedades inmunologicas de hiv-2.
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ATE110112T1 (de) * 1988-05-06 1994-09-15 Ferropas Ag Verfahren und systeme zur herstellung von hiv- antigenen.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
JP3034025B2 (ja) * 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
ATE219520T1 (de) * 1991-11-08 2002-07-15 Upjohn Co Vakzine gegen katzenleukämievirus
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP0888128A2 (en) 1995-02-10 1999-01-07 The Worcester Foundation For Biomedical Research Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
ES2143570T3 (es) * 1995-09-06 2000-05-16 Schablonentechnik Kufstein Ag Procedimiento para la fabricacion de una plantilla de serigrafia.
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839A2 (en) * 1983-05-27 1984-12-12 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
EP0173529A1 (en) * 1984-08-22 1986-03-05 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Molecular clones of the genome of HTLV-III
WO1986002383A1 (en) * 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
EP0185444A2 (en) * 1984-10-10 1986-06-25 Centocor, Inc. Cloning and expression of HTLV-III DNA
WO1986004336A1 (en) * 1985-01-21 1986-07-31 Institut Pasteur Monoclonal antibodies against core proteins of lymphadenopathy-associated-viruses
WO1986006049A1 (en) * 1985-04-17 1986-10-23 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
EP0199438A1 (en) * 1985-03-01 1986-10-29 Tse Wen Chang HTLV III Polypeptides
EP0199301A1 (en) * 1985-04-19 1986-10-29 F. Hoffmann-La Roche Ag Recombinant acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
FR2586427A1 (fr) * 1985-08-20 1987-02-27 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes
EP0181150B1 (en) * 1984-10-31 1993-06-09 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839A2 (en) * 1983-05-27 1984-12-12 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
EP0173529A1 (en) * 1984-08-22 1986-03-05 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Molecular clones of the genome of HTLV-III
EP0185444A2 (en) * 1984-10-10 1986-06-25 Centocor, Inc. Cloning and expression of HTLV-III DNA
WO1986002383A1 (en) * 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
EP0181150B1 (en) * 1984-10-31 1993-06-09 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
WO1986004336A1 (en) * 1985-01-21 1986-07-31 Institut Pasteur Monoclonal antibodies against core proteins of lymphadenopathy-associated-viruses
EP0199438A1 (en) * 1985-03-01 1986-10-29 Tse Wen Chang HTLV III Polypeptides
WO1986006049A1 (en) * 1985-04-17 1986-10-23 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
EP0199301A1 (en) * 1985-04-19 1986-10-29 F. Hoffmann-La Roche Ag Recombinant acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS
FR2586427A1 (fr) * 1985-08-20 1987-02-27 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 41, juillet 1985, pages 979-986, MIT; R. CROWL et al.: "HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients" *
NATURE, vol. 313, 7 février 1985, pages 450-458; M.A. MUESING et al.: "Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus" *
NATURE, vol. 315, no. 6015, 9 mai 1985, pages 151-154, Londres, GB; N.T. CHANG et al.: "An HTLV-III peptide produced by recombinant DNA is immunoreactive with sera from patients with AIDS" *
SCIENCE, vol. 227, 1 février 1985, pages 484-492; R. SANCHEZ-PESCADOR et al.: "Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2)" *
SCIENCE, vol. 228, 5 avril 1985, pages 93-96; N.T. CHANG et al.: "Expression in Escherichia coli of open reading frame gene segments of HTLV-III" *
VACCINES 87, Cold Spring Harbor 1986, 1987, pages 384-388; M.A. COCHRAN et al.: "Use of baculovirus recombinants as a general method for the production of subunit vaccines" *

Also Published As

Publication number Publication date
FI863848A (fi) 1987-03-26
CN1020752C (zh) 1993-05-19
YU46753B (sh) 1994-05-10
CN86106632A (zh) 1987-05-13
NO863803D0 (no) 1986-09-24
IE59314B1 (en) 1994-02-09
SE9102974D0 (sv) 1991-10-14
FR2587720B2 (zh) 1995-02-10
CH676247A5 (zh) 1990-12-28
SE9102976L (sv) 1993-04-15
WO1987002038A1 (en) 1987-04-09
IE862525L (en) 1987-03-25
SE9102975L (sv) 1993-04-15
DK455486A (da) 1987-03-26
IL80073A0 (en) 1986-12-31
ATA256786A (de) 1995-05-15
HU205780B (en) 1992-06-29
DK455486D0 (da) 1986-09-24
PT83434A (en) 1986-10-01
ES2002490A6 (es) 1988-08-16
IT8667730A0 (it) 1986-09-24
SE8604007D0 (sv) 1986-09-23
GB2181435A (en) 1987-04-23
HUT42133A (en) 1987-06-29
SE9102975D0 (sv) 1991-10-14
IL80073A (en) 1995-01-24
NO863803L (no) 1987-03-26
PT83434B (pt) 1988-07-29
GB2181435B (en) 1990-01-10
YU165486A (en) 1989-08-31
SE8604007L (sv) 1987-03-26
IT1195829B (it) 1988-10-27
MY103182A (en) 1993-05-29
SE9102976D0 (sv) 1991-10-14
FI863848A0 (fi) 1986-09-24
GB8622987D0 (en) 1986-10-29
DE3690508T1 (zh) 1988-06-23
SE9102974L (sv) 1993-04-15
GR862412B (en) 1987-01-23
ES2006941A6 (es) 1989-05-16
NL8602422A (nl) 1987-04-16
NZ217645A (en) 1991-11-26

Similar Documents

Publication Publication Date Title
FR2587720A2 (fr) Vaccin contre le syndrome immunodeficitaire acquis et intermediaires immunogeniques pour la preparation de ce vaccin et pour des dosages immunologiques de depistage de ce syndrome
Hu et al. Expression of AIDS virus envelope gene in recombinant vaccinia viruses
JP3967374B2 (ja) 同調的インビボ遺伝子発現
Mascola et al. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials
Ahmad et al. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus
JPH05503629A (ja) 抗ウィルス剤及び免疫原として使用される、非複製組換え製レトロウィルス粒子
PL188641B1 (pl) Szczepionka polienv przeciwko HIV, sposób wytwarzania szczepionki polienv,zastosowanie szczepionki polienv,zastosowanie przynajmniej jednego rekombinowanego białka env HIV lub przynajmniej jednego wektora DNA, który koduje ekspresję rekombinowanego białka env HIV, plazmid bifunkcjonalny.
Winter et al. Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice
JPH08500965A (ja) ハイブリッドウイルス発現ベクター，その使用および新規アッセイ
US5747324A (en) Self-assembled, defective, non-self-propagating lentivirus particles
JP2743164B2 (ja) Ａｉｄｓの原因ウィルスの糖蛋白質をコードするウィルスベクター及び組換えｄｎａ、該ベクターにより感染された細胞培養物、並びに抗体
JP2767078B2 (ja) Ｈｉｖ―１の分子クローンとその使用法
PT100584A (pt) Vacina contra o virus da imunodeficiencia humana a base de uma proteina recombinante do envolucro do referido virus
FI114318B (fi) Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi
ES2198400T3 (es) Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
Michel et al. HIV‐specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus
Van der Ryst et al. Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes
WO1987007642A1 (fr) Vaccin, contenant la proteine f du virus du sida
Rencher et al. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants
EP0276591B1 (fr) Vaccin constitué par un vecteur viral et ADN recombinant codant notamment pour la protéine p25 du virus agent causal du S.I.D.A.
JPS6368075A (ja) 後天性免疫不全症候群に関するワクチンおよび免疫検定法
JP2003535577A (ja) 免疫不全ウイルス用生ウイルスワクチンとしての組換えラブドウイルス
KR20010074495A (ko) 시에이이브이 및 에이치아이브이-1 유전 인자를 함유하는바이러스 키메라
US20030124146A1 (en) Recombinant Rhabdoviruses as live-viral vaccines
AU608205B2 (en) Vaccines against acquired immune deficiency syndrome